• 1
    Fontenot J.D., Rudensky A.Y. (2005) A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol;6:331337.
  • 2
    Fujinami R.S., Oldstone M.B. (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science;230:10431045.
  • 3
    Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., Dustin M.L. (1999) The immunological synapse: a molecular machine controlling T cell activation. Science;285:221227.
  • 4
    Dustin M.L. (2002) The immunological synapse. Arthritis Res Ther;4(Suppl. 3):S119125.
  • 5
    Bromley S.K., Dustin M.L. (2002) Stimulation of naive T-cell adhesion and immunological synapse formation by chemokine-dependent and -independent mechanisms. Immunology;106:289298.
  • 6
    Dustin M.L., Shaw A.S. (1999) Costimulation: building an immunological synapse. Science;283:649650.
  • 7
    Ragazzo J.L., Ozaki M.E., Karlsson L., Peterson P.A., Webb S.R. (2001) Costimulation via lymphocyte function-associated antigen 1 in the absence of CD28 ligation promotes anergy of naive CD4+ T cells. Proc Natl Acad Sci U S A;98:241246.
  • 8
    Salomon B., Bluestone J.A. (1998) LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J Immunol;161:51385142.
  • 9
    Isobe M., Yagita H., Okumura K., Ihara A. (1992) Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science;255:11251127.
  • 10
    Takazawa K., Hosoda Y., Bashuda H., Seino K., Yagita H., Tamatani T., Miyasaka M., Okumura K. (1996) Synergistic effects of mycophenolate mofetil (MMF, RS-61443) and anti-LFA-1/ICAM-1 monoclonal antibodies on the prolongation of heart allograft survival in rats. Transplant Proc;28:19801981.
  • 11
    Schulze-Koops H., Lipsky P.E., Kavanaugh A.F., Davis L.S. (1995) Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol;155:50295037.
  • 12
    Kavanaugh A.F., Davis L.S., Jain R.I., Nichols L.A., Norris S.H., Lipsky P.E. (1996) A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol;23:13381344.
  • 13
    Barouch F.C., Miyamoto K., Allport J.R., Fujita K., Bursell S.E., Aiello L.P., Luscinskas F.W., Adamis A.P. (2000) Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci;41:11531158.
  • 14
    Moriyama H., Yokono K., Amano K., Nagata M., Hasegawa Y., Okamoto N., Tsukamoto K. et al. (1996) Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol;157:37373743.
  • 15
    Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., Garovoy M. (2002) Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol;138:591600.
  • 16
    Papp K., Bissonnette R., Krueger J.G., Carey W., Gratton D., Gulliver W.P., Lui H. et al. (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol;45:665674.
  • 17
    Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med;7:687692.
  • 18
    Kelly T.A., Jeanfavre D.D., McNeil D.W., Woska J.R. Jr, Reilly P.L., Mainolfi E.A., Kishimoto K.M., Nabozny G.H., Zinter R., Bormann B.J., Rothlein R. (1999) Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol;163:51735177.
  • 19
    Last-Barney K., Davidson W., Cardozo M., Frye L.L., Grygon C.A., Hopkins J.L., Jeanfavre D.D., Pav S., Qian C., Stevenson J.M., Tong L., Zindell R., Kelly T.A. (2001) Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein-protein interaction. J Am Chem Soc;123:56435650.
  • 20
    Liu G., Huth J.R., Olejniczak E.T., Mendoza R., DeVries P., Leitza S., Reilly E.B., Okasinski G.F., Fesik S.W., Von Geldern T.W. (2001) Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction: 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J Med Chem;44:12021210.
  • 21
    Qu A., Leahy D.J. (1996) The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin. Structure;4:931942.
  • 22
    Van Kooyk Y., Figdor C.G. (2000) Avidity regulation of integrins: the driving force in leukocyte adhesion. Curr Opin Cell Biol;12:542547.
  • 23
    Haverstick D.M., Sakai H., Gray L.S. (1992) Lymphocyte adhesion can be regulated by cytoskeleton-associated, PMA-induced capping of surface receptors. Am J Physiol;262:C916926.
  • 24
    Larson R.S., Davis T., Bologa C., Semenuk G., Vijayan S., Li Y., Oprea T., Chigaev A., Buranda T., Wagner C.R., Sklar L.A. (2005) Dissociation of I domain and global conformational changes in LFA-1: refinement of small molecule-I domain structure-activity relationships. Biochemistry;44:43224331.
  • 25
    Tibbetts S.A., Chirathaworn C., Nakashima M., Jois D.S., Siahaan T.J., Chan M.A., Benedict S.H. (1999) Peptides derived from ICAM-1 and LFA-1 modulate T cell adhesion and immune function in a mixed lymphocyte culture. Transplantation;68:685692.
  • 26
    Tibbetts S.A., Seetharama Jois D., Siahaan T.J., Benedict S.H., Chan M.A. (2000) Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function. Peptides;21:11611167.
  • 27
    Anderson M.E., Siahaan T.J. (2003) Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery. Pharm Res;20:15231532.
  • 28
    Anderson M.E., Yakovleva T., Hu Y., Siahaan T.J. (2004) Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg Med Chem Lett;14:13991402.
  • 29
    Gursoy R.N., Jois D.S., Siahaan T.J. (1999) Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys-OH. J Pept Res;53:422431.
  • 30
    Jois D.S., Pal D., Tibbetts S.A., Chan M.A., Benedict S.H., Siahaan T.J. (1997) Inhibition of homotypic adhesion of T-cells: secondary structure of an ICAM-1-derived cyclic peptide. J Pept Res;49:517526.
  • 31
    Casasnovas J.M., Stehle T., Liu J.H., Wang J.H., Springer T.A. (1998) A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc Natl Acad Sci U S A;95:41344139.
  • 32
    Ruoslahti E., Pierschbacher M.D. (1987) New perspectives in cell adhesion: RGD and integrins. Science;238:491497.
  • 33
    Qu A., Leahy D.J. (1995) Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, aLb_2) integrin. Proc Natl Acad Sci U S A;92:1027710281.
  • 34
    Huth J.R., Olejniczak E.T., Mendoza R., Liang H., Harris E.A., Lupher M.L. Jr, Wilson A.E., Fesik S.W., Staunton D.E. (2000) NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc Natl Acad Sci U S A;97:52315236.
  • 35
    Dransfield I., Cabanas C., Craig A., Hogg N. (1992) Divalent cation regulation of the function of the leukocyte integrin LFA-1. J Cell Biol;116:219226.
  • 36
    Dransfield I., Hogg N. (1989) Regulated expression of Mg2+ binding epitope on leukocyte integrin a subunits. EMBO J;8:37593765.
  • 37
    Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G., Cottens S., Weitz-Schmidt G., Hommel U. (1999) Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol;292:19.
  • 38
    Woska J.R. Jr, Rothlein R., Lemieux R.M., Reiser H.C., Caviness G.O., Kishimoto T., Last-Barney K. (2005) Methods and Molecules Useful for Identifying Molecules that Bind LFA-1 and for Determining Receptor Occupancy. US Patent 6846643.
  • 39
    Lu C., Shimaoka M., Salas A., Springer T.A. (2004) The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. J Immunol;173:39723978.
  • 40
    Xiong Y.M., Zhang L. (2001) Structure-function of the putative I-domain within the integrin b2 subunit. J Biol Chem;276:1934019349.
  • 41
    Huang C., Zang Q., Takagi J., Springer T.A. (2000) Structural and functional studies with antibodies to the integrin b2 subunit. A model for the I-like domain. J Biol Chem;275:2151421524.
  • 42
    Woska J.R. Jr, Shih D., Taqueti V.R., Hogg N., Kelly T.A., Kishimoto T.K. (2001) A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J Leukoc Biol;70:329334.
  • 43
    Ma Q., Shimaoka M., Lu C., Jing H., Carman C.V., Springer T.A. (2002) Activation-induced conformational changes in the I domain region of lymphocyte function-associated antigen 1. J Biol Chem;277:1063810641.
  • 44
    Huang C., Springer T.A. (1997) Folding of the b-propeller domain of the integrin aL subunit is independent of the I domain and dependent on the b2 subunit. Proc Natl Acad Sci U S A; 94:31623167.
  • 45
    Ruoslahti E., Pierschbacher M.D. (1986) Arg-Gly-Asp: a versatile cell recognition signal. Cell;44:517518.
  • 46
    Marinelli L., Lavecchia A., Gottschalk K.E., Novellino E., Kessler H. (2003) Docking studies on avb_3 integrin ligands: pharmacophore refinement and implications for drug design. J Med Chem;46:43934404.
  • 47
    Pierschbacher M.D., Ruoslahti E. (1987) Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem;262:1729417298.
  • 48
    Peishoff C.E., Ali F.E., Bean J.W., Calvo R., D'Ambrosio C.A., Eggleston D.S., Huang S.M. et al. (1992) Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides. J Med Chem;35:39623969.
  • 49
    Kim M., Carman C.V., Yang W., Salas A., Springer T.A. (2004) The primacy of affinity over clustering in regulation of adhesiveness of the integrin aLb_2. J Cell Biol;167:12411253.
  • 50
    Yusuf-Makagiansar H., Siahaan T.J. (2001) Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharm Res;18:329335.
  • 51
    Gursoy R.N., Siahaan T.J. (1999) Binding and internalization of an ICAM-1 peptide by the surface receptors of T cells. J Pept Res;53:414421.
  • 52
    Almenar-Queralt A., Duperray A., Miles L.A., Felez J., Altieri D.C. (1995) Apical topography and modulation of ICAM-1 expression on activated endothelium. Am J Pathol;147:12781288.
  • 53
    Raub T.J., Kuentzel S.L. (1989) Kinetic and morphological evidence for endocytosis of mammalian cell integrin receptors by using an anti-fibronectin receptor b subunit monoclonal antibody. Exp Cell Res;184:407426.
  • 54
    Ricard I., Payet M.D., Dupuis G. (1998) VCAM-1 is internalized by a clathrin-related pathway in human endothelial cells but its a4b_1 integrin counter-receptor remains associated with the plasma membrane in human T lymphocytes. Eur J Immunol;28:17081718.
  • 55
    Chambers J.D., Simon S.I., Berger E.M., Sklar L.A., Arfors K.E. (1993) Endocytosis of b2 integrins by stimulated human neutrophils analyzed by flow cytometry. J Leukoc Biol;53:462469.